Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Correction: Prevalence and predictors for sustained remission in rheumatoid arthritis.

Sung YK, Yoshida K, Prince FHM, Frits ML, Cho SK, Choe JY, Lee HS, Lee J, Lee SS, Yoo DH, Helfgott SM, Shadick NA, Weinblatt ME, Solomon DH, Bae SC.

PLoS One. 2019 Aug 14;14(8):e0221314. doi: 10.1371/journal.pone.0221314. eCollection 2019.

2.

Prevalence and predictors for sustained remission in rheumatoid arthritis.

Sung YK, Yoshida K, Prince FHM, Frits ML, Cho SK, Choe JY, Lee HS, Lee J, Lee SS, Yoo DH, Helfgott SM, Shadick NA, Weinblatt ME, Solomon DH, Bae SC.

PLoS One. 2019 Apr 19;14(4):e0214981. doi: 10.1371/journal.pone.0214981. eCollection 2019. Erratum in: PLoS One. 2019 Aug 14;14(8):e0221314.

3.

Mixed-effects association of single cells identifies an expanded effector CD4+ T cell subset in rheumatoid arthritis.

Fonseka CY, Rao DA, Teslovich NC, Korsunsky I, Hannes SK, Slowikowski K, Gurish MF, Donlin LT, Lederer JA, Weinblatt ME, Massarotti EM, Coblyn JS, Helfgott SM, Todd DJ, Bykerk VP, Karlson EW, Ermann J, Lee YC, Brenner MB, Raychaudhuri S.

Sci Transl Med. 2018 Oct 17;10(463). pii: eaaq0305. doi: 10.1126/scitranslmed.aaq0305.

4.

Analysis of pulmonary features and treatment approaches in the COPA syndrome.

Tsui JL, Estrada OA, Deng Z, Wang KM, Law CS, Elicker BM, Jones KD, Dell SD, Gudmundsson G, Hansdottir S, Helfgott SM, Volpi S, Gattorno M, Waterfield MR, Chan AY, Chung SA, Ley B, Shum AK.

ERJ Open Res. 2018 Jun 27;4(2). pii: 00017-2018. doi: 10.1183/23120541.00017-2018. eCollection 2018 Apr.

5.

Disclosure of Personalized Rheumatoid Arthritis Risk Using Genetics, Biomarkers, and Lifestyle Factors to Motivate Health Behavior Improvements: A Randomized Controlled Trial.

Sparks JA, Iversen MD, Yu Z, Triedman NA, Prado MG, Miller Kroouze R, Kalia SS, Atkinson ML, Mody EA, Helfgott SM, Todd DJ, Dellaripa PF, Bermas BL, Costenbader KH, Deane KD, Lu B, Green RC, Karlson EW.

Arthritis Care Res (Hoboken). 2018 Jun;70(6):823-833. doi: 10.1002/acr.23411. Epub 2018 Apr 16.

6.

Calcium Pyrophosphate Crystal Inflammatory Arthritis (Pseudogout) with Myelodysplastic Syndrome: A New Paraneoplastic Syndrome?

Tedeschi SK, Stone RM, Helfgott SM.

J Rheumatol. 2017 Jul;44(7):1101-1102. doi: 10.3899/jrheum.170106. No abstract available.

7.

Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis.

Rao DA, Gurish MF, Marshall JL, Slowikowski K, Fonseka CY, Liu Y, Donlin LT, Henderson LA, Wei K, Mizoguchi F, Teslovich NC, Weinblatt ME, Massarotti EM, Coblyn JS, Helfgott SM, Lee YC, Todd DJ, Bykerk VP, Goodman SM, Pernis AB, Ivashkiv LB, Karlson EW, Nigrovic PA, Filer A, Buckley CD, Lederer JA, Raychaudhuri S, Brenner MB.

Nature. 2017 Feb 1;542(7639):110-114. doi: 10.1038/nature20810.

8.

Respiratory and otolaryngologic manifestations of giant cell arteritis.

Imran TF, Helfgott S.

Clin Exp Rheumatol. 2015 Mar-Apr;33(2 Suppl 89):S-164-70. Epub 2015 May 26. Review.

PMID:
26016768
9.

Neurologic complications of systemic lupus erythematosus, sjögren syndrome, and rheumatoid arthritis.

Bhattacharyya S, Helfgott SM.

Semin Neurol. 2014 Sep;34(4):425-36. doi: 10.1055/s-0034-1390391. Epub 2014 Nov 4. Review.

PMID:
25369438
10.

Emerging therapies for systemic lupus erythematosus--focus on targeting interferon-alpha.

Lichtman EI, Helfgott SM, Kriegel MA.

Clin Immunol. 2012 Jun;143(3):210-21. doi: 10.1016/j.clim.2012.03.005. Epub 2012 Apr 6. Review.

11.

The research-based rheumatologist: strategies to remove the species from the endangered list.

Helfgott S.

Arthritis Rheum. 2010 Dec;62(12):3522-3. doi: 10.1002/art.27718. No abstract available.

12.

The relationship between disease activity, sleep, psychiatric distress and pain sensitivity in rheumatoid arthritis: a cross-sectional study.

Lee YC, Chibnik LB, Lu B, Wasan AD, Edwards RR, Fossel AH, Helfgott SM, Solomon DH, Clauw DJ, Karlson EW.

Arthritis Res Ther. 2009;11(5):R160. doi: 10.1186/ar2842. Epub 2009 Oct 29.

13.

Use of the T-SPOT.TB assay to detect latent tuberculosis infection among rheumatic disease patients on immunosuppressive therapy.

Behar SM, Shin DS, Maier A, Coblyn J, Helfgott S, Weinblatt ME.

J Rheumatol. 2009 Mar;36(3):546-51. doi: 10.3899/jrheum.080854. Epub 2009 Feb 17.

PMID:
19228655
14.

Clinical problem-solving. A joint venture.

Schwarzberg AB, Alexander CB, DeAngelo DJ, Helfgott SM.

N Engl J Med. 2008 Jun 5;358(23):2496-501. doi: 10.1056/NEJMcps070565. No abstract available.

PMID:
18525046
15.

Development of active tuberculosis following initiation of infliximab despite appropriate prophylaxis.

Raychaudhuri S, Shmerling R, Ermann J, Helfgott S.

Rheumatology (Oxford). 2007 May;46(5):887-8. Epub 2007 Mar 15. No abstract available.

16.

Serum sickness following treatment with rituximab.

Todd DJ, Helfgott SM.

J Rheumatol. 2007 Feb;34(2):430-3.

PMID:
17295433
17.

Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study.

Johnsen AK, Schiff MH, Mease PJ, Moreland LW, Maier AL, Coblyn JS, Helfgott SM, Leff JA, Weinblatt ME.

J Rheumatol. 2006 Apr;33(4):659-64. Epub 2006 Feb 15.

PMID:
16482646
19.

Sensible approach to low back pain.

Helfgott SM.

Bull Rheum Dis. 2001;50(3):1-4. Review. No abstract available.

PMID:
12386944
20.

Whither the drug specialist? The work-force development needs of drug specialist staff and agencies.

Allsop SJ, Helfgott S.

Drug Alcohol Rev. 2002 Sep;21(3):215-22. Review.

PMID:
12270071
22.

Leflunomide-associated weight loss in rheumatoid arthritis.

Coblyn JS, Shadick N, Helfgott S.

Arthritis Rheum. 2001 May;44(5):1048-51.

23.

Patterns of medication use before and after bone densitometry: factors associated with appropriate treatment.

Solomon DH, Levin E, Helfgott SM.

J Rheumatol. 2000 Jun;27(6):1496-500.

PMID:
10852277
24.

Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis.

Weinblatt ME, Kremer JM, Coblyn JS, Maier AL, Helfgott SM, Morrell M, Byrne VM, Kaymakcian MV, Strand V.

Arthritis Rheum. 1999 Jul;42(7):1322-8.

25.

Stiff-man syndrome: from the bedside to the bench.

Helfgott SM.

Arthritis Rheum. 1999 Jul;42(7):1312-20. Review.

26.
27.

Polymyalgia rheumatica in patients with a normal erythrocyte sedimentation rate.

Helfgott SM, Kieval RI.

Arthritis Rheum. 1996 Feb;39(2):304-7.

PMID:
8849384
28.

Polyarthritis in a 78-year-old woman.

Gravallese EM, Winalski CS, Longtine J, Helfgott SM.

Arthritis Rheum. 1994 Jul;37(7):1087-95. No abstract available.

PMID:
8024617
29.

Treatment of stiff-man syndrome with intravenous immune globulin.

Karlson EW, Sudarsky L, Ruderman E, Pierson S, Scott M, Helfgott SM.

Arthritis Rheum. 1994 Jun;37(6):915-8.

PMID:
8003064
30.

Nabumetone: a clinical appraisal.

Helfgott SM.

Semin Arthritis Rheum. 1994 Apr;23(5):341-6. Review.

PMID:
8036523
31.

Herpes zoster radiculopathy.

Helfgott SM, Picard DA, Cook JS.

Spine (Phila Pa 1976). 1993 Dec;18(16):2523-4.

PMID:
8303458
32.

Misinterpretation of serum transaminase elevation in "occult" myositis.

Helfgott SM, Karlson E, Beckman E.

Am J Med. 1993 Oct;95(4):447-9. No abstract available.

PMID:
8213881
33.

Zileuton, a 5-lipoxygenase inhibitor in rheumatoid arthritis.

Weinblatt ME, Kremer JM, Coblyn JS, Helfgott S, Maier AL, Petrillo G, Henson B, Rubin P, Sperling R.

J Rheumatol. 1992 Oct;19(10):1537-41.

PMID:
1334515
34.

Scapholunate dissociation associated with crystal induced synovitis.

Helfgott SM, Skoff H.

J Rheumatol. 1992 Mar;19(3):485-7.

PMID:
1578468
35.

The effects of cyclosporin A on eicosanoid excretion in patients with rheumatoid arthritis.

Weinblatt M, Helfgott S, Coblyn J, Spragg J, Uedelhoven WM, Tumeh S, Sperling R, Lorenz R, Maier A, Weber P.

Arthritis Rheum. 1991 Apr;34(4):481-5.

PMID:
2012627
36.

Correlation between antibodies to type II collagen and treatment outcome in bilateral progressive sensorineural hearing loss.

Helfgott SM, Mosciscki RA, San Martin J, Lorenzo C, Kieval R, McKenna M, Nadol J, Trentham DE.

Lancet. 1991 Feb 16;337(8738):387-9.

PMID:
1671423
37.

Diclofenac-associated hepatotoxicity.

Helfgott SM, Sandberg-Cook J, Zakim D, Nestler J.

JAMA. 1990 Nov 28;264(20):2660-2.

PMID:
2232043
38.

Cricoarytenoid synovitis in ankylosing spondylitis.

Helfgott SM, Treseler PA.

Arthritis Rheum. 1990 Apr;33(4):604-5. No abstract available.

PMID:
2328038
39.

Total lymphoid irradiation.

Helfgott SM.

Rheum Dis Clin North Am. 1989 Aug;15(3):577-82. Review.

PMID:
2672139
40.

Unusual features of iliopsoas bursitis.

Helfgott SM.

Arthritis Rheum. 1988 Oct;31(10):1331-3. No abstract available.

PMID:
3178913
41.

Cooccurrence of rheumatoid arthritis and ankylosing spondylitis.

Helfgott SM, Lazarides G, Sandberg-Cook J.

J Rheumatol. 1988 Sep;15(9):1451-2. No abstract available.

PMID:
3199405
42.

Intraarticular injection of arthritogenic factor causes mast cell degranulation, inflammation, fat necrosis, and synovial hyperplasia.

Caulfield JP, Hein A, Helfgott SM, Brahn E, Dynesius-Trentham RA, Trentham DE.

Lab Invest. 1988 Jul;59(1):82-95.

PMID:
3392961
43.

Detection of arthritogenic factor in adjuvant arthritis.

Helfgott SM, Kieval RI, Breedveld FC, Brahn E, Young CT, Dynesius-Trentham R, Trentham DE.

J Immunol. 1988 Mar 15;140(6):1838-43.

PMID:
3257989
44.

Pedal gangrene caused by giant cell arteritis.

Helfgott SM, Bauer MR.

Arthritis Rheum. 1987 Sep;30(9):1078-9. No abstract available.

PMID:
3663260
45.

An arthritogenic lymphokine in the rat.

Helfgott SM, Dynesius-Trentham R, Brahn E, Trentham DE.

J Exp Med. 1985 Nov 1;162(5):1531-45.

46.

Suppressive effects of anti-mu serum on the development of collagen arthritis in rats.

Helfgott SM, Bazin H, Dessein A, Trentham DE.

Clin Immunol Immunopathol. 1984 Jun;31(3):403-11.

PMID:
6424991
47.

Total lymphoid irradiation therapy in refractory rheumatoid arthritis. Fifteen- to forty-month followup.

Brahn E, Helfgott SM, Belli JA, Anderson RJ, Reinherz EL, Schlossman SF, Austen KF, Trentham DE.

Arthritis Rheum. 1984 May;27(5):481-8.

PMID:
6609705
48.

Generalized skeletal response to 99mtechnetium methylene diphosphonate in rheumatoid arthritis.

Helfgott S, Rosenthall L, Esdaile J, Tannenbaum H.

J Rheumatol. 1982 Nov-Dec;9(6):939-41.

PMID:
6219221
49.

Radiophosphate imaging of regional migratory osteoporosis.

Helfgott S, Tannenbaum H, Rosenthall L.

Clin Nucl Med. 1979 Aug;4(8):330-2.

PMID:
466913

Supplemental Content

Loading ...
Support Center